Schlossmacher Michael G, Tomlinson Julianna J, Santos Goncalo, Shutinoski Bojan, Brown Earl G, Manuel Douglas, Mestre Tiago
Neuroscience Program, Ottawa Hospital Research Institute, 451 Smyth Road, RGH #1414, Ottawa, ON, K1H 8M5, Canada.
Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, Canada.
Eur J Neurosci. 2017 Jan;45(1):175-191. doi: 10.1111/ejn.13476. Epub 2016 Dec 27.
Fifty-five years after the concept of dopamine replacement therapy was introduced, Parkinson disease (PD) remains an incurable neurological disorder. To date, no disease-modifying therapeutic has been approved. The inability to predict PD incidence risk in healthy adults is seen as a limitation in drug development, because by the time of clinical diagnosis ≥ 60% of dopamine neurons have been lost. We have designed an incidence prediction model founded on the concept that the pathogenesis of PD is similar to that of many disorders observed in ageing humans, i.e. a complex, multifactorial disease. Our model considers five factors to determine cumulative incidence rates for PD in healthy adults: (i) DNA variants that alter susceptibility (D), e.g. carrying a LRRK2 or GBA risk allele; (ii) Exposure history to select environmental factors including xenobiotics (E); (iii) Gene-environment interactions that initiate pathological tissue responses (I), e.g. a rise in ROS levels, misprocessing of amyloidogenic proteins (foremost, α-synuclein) and dysregulated inflammation; (iv) sex (or gender; G); and importantly, (v) time (T) encompassing ageing-related changes, latency of illness and propagation of disease. We propose that cumulative incidence rates for PD (P ) can be calculated in healthy adults, using the formula: P (%) = (E + D + I) × G × T. Here, we demonstrate six case scenarios leading to young-onset parkinsonism (n = 3) and late-onset PD (n = 3). Further development and validation of this prediction model and its scoring system promise to improve subject recruitment in future intervention trials. Such efforts will be aimed at disease prevention through targeted selection of healthy individuals with a higher prediction score for developing PD in the future and at disease modification in subjects that already manifest prodromal signs.
在多巴胺替代疗法的概念提出55年后,帕金森病(PD)仍然是一种无法治愈的神经疾病。迄今为止,尚无获批的疾病修饰疗法。无法预测健康成年人患PD的发病风险被视为药物研发中的一个限制因素,因为在临床诊断时,≥60%的多巴胺神经元已经丧失。我们设计了一种发病率预测模型,其基于这样的概念,即PD的发病机制与在老年人群中观察到的许多疾病相似,也就是一种复杂的多因素疾病。我们的模型考虑五个因素来确定健康成年人患PD的累积发病率:(i)改变易感性的DNA变异(D),例如携带LRRK2或GBA风险等位基因;(ii)对包括外源性物质在内的特定环境因素的暴露史(E);(iii)引发病理性组织反应的基因-环境相互作用(I),例如活性氧水平升高、淀粉样蛋白(主要是α-突触核蛋白)加工错误和炎症调节异常;(iv)性别(G);重要的是,(v)涵盖与衰老相关变化、疾病潜伏期和疾病传播的时间(T)。我们提出,可以使用公式P(%)=(E + D + I)×G×T来计算健康成年人患PD的累积发病率。在此,我们展示了导致早发性帕金森综合征(n = 3)和晚发性PD(n = 3)的六种病例情况。该预测模型及其评分系统的进一步开发和验证有望改善未来干预试验中的受试者招募。此类努力将旨在通过有针对性地选择未来患PD预测评分较高的健康个体来预防疾病,并针对已经表现出前驱症状的受试者进行疾病修饰。